Bain Capital and Cinven acquire Stada - Owner of Hemofarm sold at EUR 5,4 billion

Illustration (Photo: Pavel Kubarkov/shutterstock.com)

Buyers succeeded in reaching a minimum required for takeover of 63% shares, where bidder was ready, after correction of that threshold from initial 75% shares, New York agency reports, stating announcement published at the official website of Stada group.

All agreements of anti monopoly regulators were provided and offered shares will be transferred before the end of the month, it was stated in the announcement of drugs producer from Bad Vilbel.

Vrsac-based Hemofarm has also been operating within German pharmaceutical giant since 2006.